Internal Medicine, Endocrinology, Diabetes, & Metabolism · Tampa, FL
NPI
1194110361
Since 2015
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
17 Davis Blvd Ste 308
Tampa, FL, 33606
Phone (813) 259-0661
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,276
154 services
Medicare patients, 2024
52
Average age 73
Drug cost, 2024
$5.5M
14,234 prescriptions
Company payments, 2025
$874
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Carlos A Pla Fernandez was code 99213 (office e&m - established), 52 times for 34 patients. In total Carlos A Pla Fernandez billed 154 services in 10 codes, and Medicare paid $9,276.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-07-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 52 | 34 | $53.29 | $2,771 |
| 99214 Office E&M - Established | Office | 22 | 16 | $78.72 | $1,732 |
By year: 2022 $8,547 for 103 services; 2023 $7,802 for 109 services; 2024 $9,276 for 154 services.
Medicare prescription drug claims, 2024
In 2024, the drug Carlos A Pla Fernandez prescribed most often to Medicare patients was Trulicity (Dulaglutide), with 1,578 prescriptions and refills. In total Carlos A Pla Fernandez wrote 14,234 Medicare prescriptions that cost $5.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trulicity Dulaglutide | 1,578 | 1,621 | 207 | $1.6M |
| Pioglitazone Hcl Generic | 1,463 | 2,647 | 339 | $25K |
| Synthroid Levothyroxine Sodium | 965 | 2,068 | 255 | $93K |
| Mounjaro Tirzepatide | 680 | 693 | 96 | $741K |
| Ozempic Semaglutide | 676 | 689 | 96 | $674K |
| Lantus Insulin Glargine,hum.Rec.Anlog | 513 | 753 | 118 | $59K |
| Atorvastatin Calcium Generic | 500 | 1,017 | 131 | $5,632 |
| Glipizide Er Glipizide | 453 | 795 | 111 | $10K |
| Jardiance Empagliflozin | 453 | 583 | 88 | $357K |
| Farxiga Dapagliflozin Propanediol | 421 | 523 | 82 | $304K |
| Glipizide Generic | 416 | 591 | 87 | $6,160 |
| Synjardy Xr Empagliflozin/Metformin Hcl | 259 | 455 | 58 | $254K |
| Metformin Hcl Generic | 243 | 527 | 81 | $1,844 |
| Trijardy Xr Empaglifloz/Linaglip/Metformin | 241 | 333 | 51 | $203K |
| Gabapentin Generic | 220 | 378 | 62 | $2,729 |
Brand drugs: 7,781 claims; generic drugs: 5,955 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Carlos A Pla Fernandez $874 ($874 in general payments such as food, travel and fees) from 7 companies. The largest payer was Novo Nordisk Inc with $259.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.